Syngene to acquire multi-modal facility from Stelis Biopharma
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
The expansion makes Exothera one of the largest viral vector facilities in Europe
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Subscribe To Our Newsletter & Stay Updated